002007.SZ
华兰生物
SZSE · Healthcare · C 制造业 · CN
CNY 12.84
−2.51%Year over year
Reported trailing growth
- Revenue
- +0.7%
- EBITDA
- —
- EBIT
- -21.9%
- EPS
- -24.7%
- Free cash flow
- +66.4%
- Operating cash flow
- -16.2%
Forward estimates
Based on analyst estimates
- Revenue
- -10.2%
- EBITDA
- -5.9%
- EPS
- +0.1%
Three-year CAGR
- Revenue
- +0.6%
- EBITDA
- -4.1%
- EBIT
- -4.8%
- Net income
- -4.4%
- EPS
- -4.4%
- Free cash flow
- +6.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026